Quantcast

Latest Moclobemide Stories

2011-01-06 06:30:00

RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2011 /PRNewswire/ -- CeNeRx BioPharma, Inc., today reported that it has initiated a Phase II trial of its new formulation of TriRima(TM), the company's novel antidepressant in development as monotherapy for treatment resistant depression. CeNeRx also announced that it will be presenting at Biotech Showcase(TM) 2011 on Tuesday, January 11, 2011 at 11:00 AM PST. TriRima is a member of a novel class of drugs known as RIMAs, or reversible and selective...

2010-11-02 06:30:00

RESEARCH TRIANGLE PARK, N.C., Nov. 2, 2010 /PRNewswire/ -- CeNeRx BioPharma, Inc., today announced that a new formulation of TriRima(TM), its lead agent for treatment resistant depression, showed excellent safety in a study designed to test whether it is free of the food-induced cardiovascular effects associated with conventional MAO inhibitors. These positive results further confirm the good safety profile demonstrated by TriRima in Phase I studies and set the stage for a TriRima...

2010-01-07 14:08:49

Monoamine oxidase-A inhibitor drug blocks buildup of toxic free radicals in animal hearts A team of Johns Hopkins and other researchers have found in animal experiments that an antidepressant developed over 40 years ago can blunt and even reverse the muscle enlargement and weakened pumping function associated with heart failure. In a report to be published in the Jan. 8 edition of the journal Circulation Research, the international team of U.S. and Italian heart experts describes in a dozen...

2008-10-17 09:00:06

RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced that it has initiated a Phase II clinical trial for its lead product candidate Tyrima(TM) for the treatment of major depressive disorder (MDD). Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A...

2008-08-15 03:00:33

Regulatory News: Meda (STO:MEDAA) has reached an agreement with the Swiss pharma company Roche to acquire four of their well-established pharmaceutical products. The acquired products have strong brand names and the total sales level is 500 MSEK. No employees will transfer from Roche to Meda in conjunction with the acquisition. Meda acquires world-wide rights to the products and the most important markets are Germany, Spain, Switzerland, USA and France. Meda strengthens its position in...

2008-07-22 09:00:21

RESEARCH TRIANGLE PARK, N.C., July 22 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced plans to advance its lead candidate Tyrima(TM) into Phase II trials for the treatment of depression and anxiety. This milestone is based on the positive results of the Tyrima Phase I program reported earlier this year and the recent completion of PET brain imaging studies showing...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.